Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (symbol: NLTX) is a cutting-edge biopharmaceutical company focused on the development of next-generation immunotherapies. Using advanced de novo protein design technology, Neoleukin creates synthetic proteins with specific pharmaceutical properties designed to treat cancer, inflammation, and autoimmune diseases.
In recent developments, Neoleukin has implemented a reverse stock split, approved by its stockholders at the 2023 Annual Meeting held on June 8, 2023, and executed by the Board on August 30, 2023. This reverse stock split reduces the number of shares of common stock from approximately 44,026,429 to about 8,805,285, while also adjusting the number of authorized shares from 100,000,000 to 20,000,000. While this adjustment affects all stockholders uniformly, it simplifies stock management without altering any stockholder’s ownership percentage, except for those receiving cash in lieu of fractional shares.
As of March 2023, Neoleukin restructured its operations to conserve capital. This strategic move was part of an overarching plan to streamline operations while focusing on its core competencies. The company continues to leverage its sophisticated computational methods to develop proteins with superior therapeutic benefits compared to native proteins. Neoleukin's innovation has positioned it as a leader in the biotechnology sector, providing advanced solutions for complex health challenges.
Furthermore, a proposed merger and its anticipated impacts on the company’s stock and listing on the Nasdaq Capital Market are key topics for investors. The merger is expected to result in a combined total of approximately 13,676,732 shares of outstanding common stock.
For more information, please visit the Neoleukin website or contact Neoleukin's investor relations and media teams at investors@neoleukin.com.
Neoleukin Therapeutics (NASDAQ:NLTX) reported Q2 2021 results highlighting key progress in its clinical pipeline. The lead candidate, NL-201, is undergoing a Phase 1 trial for advanced solid tumors, with interim data expected in 2022. The company reported a cash position of $164.2 million, down from $192.6 million at year-end 2020, sufficient to fund operations into 2023. R&D expenses surged to $9.8 million, reflecting increased trial activities. The net loss for Q2 was $15.1 million, up from $9.7 million in Q2 2020. Neoleukin is prioritizing NL-201's development despite some pandemic-related delays.
Neoleukin Therapeutics (NASDAQ:NLTX) announced CEO Jonathan Drachman will join a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 8:00 a.m. ET. The event will feature a live audio webcast, accessible through the investor section of Neoleukin's website, along with an archived replay available for 30 days post-event. Neoleukin specializes in immunotherapies for cancer and autoimmune diseases through its innovative de novo protein design technology, with its lead candidate being NL-201, a combined IL-2 and IL-15 agonist.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET. The event will include a live audio webcast available on Neoleukin's investor website, with an archived replay accessible for 30 days post-event. Neoleukin specializes in designing de novo protein therapeutics aimed at treating cancer, inflammation, and autoimmunity. Its lead candidate, NL-201, is an IL-2 and IL-15 agonist, promising enhanced efficacy and tolerability.
Neoleukin Therapeutics (NASDAQ:NLTX) has initiated a Phase 1 trial for NL-201, with the first patient dosed in May 2021. The trial aims to evaluate NL-201's safety and efficacy in advanced solid tumors. Neoleukin reported a cash position of $178.4 million as of March 31, 2021, which is expected to fund operations into 2023. The R&D expenses increased to $9.7 million, and the net loss for Q1 2021 was $14.9 million. Additionally, Dr. Priti Patel was appointed as Chief Medical Officer, enhancing the leadership team.
Neoleukin Therapeutics (NASDAQ:NLTX) has initiated a Phase 1 clinical trial for NL-201, targeting patients with advanced solid tumors. The trial, which has commenced with the first patient dosed in Australia, aims to enroll up to 120 patients to evaluate the safety and efficacy of NL-201, a novel protein designed to mimic IL-2 and IL-15. Key objectives include assessing safety, pharmacokinetics, and potential anti-tumor activity. Neoleukin anticipates expanding the study to specific cohorts, including those with renal cell carcinoma and melanoma.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ as NLTX, will have its CEO, Jonathan Drachman, participate in a fireside chat at the BofA Securities 2021 Healthcare Conference on May 12, 2021, at 10:15 a.m. ET. A live audio webcast will be available on Neoleukin's investor website, with an archived replay accessible for at least 30 days post-event. Neoleukin focuses on creating innovative immunotherapies through de novo protein design technology, with its lead candidate, NL-201, aimed at improving tolerability and effectiveness in therapeutic applications.
Neoleukin Therapeutics (NASDAQ:NLTX) appointed Dr. Priti Patel as Chief Medical Officer. Bringing extensive experience from AstraZeneca, where she led clinical development in hematology, Dr. Patel's background includes overseeing over 6 Phase 3 and 20 Phase 1/2 studies. CEO Jonathan Drachman highlighted her expertise as vital for initiating the clinical trial of NL-201 and shaping future strategies. Neoleukin focuses on innovative therapies utilizing de novo protein design technology, with NL-201 being a lead candidate aimed at enhancing cancer treatment.
Neoleukin Therapeutics (NASDAQ: NLTX) has announced the lifting of a clinical hold by the FDA for its Phase 1 trial of NL-201, an immunotherapeutic candidate. Previously, the FDA required a new assay to ensure accurate dosing of NL-201. The Phase 1 study aims to evaluate NL-201's safety and preliminary efficacy in treating advanced solid tumors in up to 120 patients across North America and Australia. NL-201 functions as a receptor agonist for IL-2 and IL-15, designed to enhance the proliferation of cancer-fighting CD8 T and NK cells while reducing regulatory T cell interference.
Neoleukin Therapeutics (NASDAQ:NLTX) provided a corporate update and financial results for the year ended December 31, 2020. The company anticipates initiating its NL-201 Phase 1 trial in Australia in the first half of 2021. Cash and cash equivalents stand at $192.6 million, expected to fund operations into 2023. Research and development expenses increased to $24.3 million, reflecting heightened IND-enabling activities. Neoleukin reported a net loss of $33.3 million for 2020, a reduction from $69.4 million in 2019. The company plans to host a conference call on March 25, 2021.
Neoleukin Therapeutics (NASDAQ:NLTX) will report its full year 2020 financial results on March 25, 2021, after market close. A conference call and audio webcast will follow at 1:30 PM Pacific / 4:30 PM Eastern to discuss these results and provide updates on the company’s developments, particularly regarding its lead product candidate NL-201, an immunotherapy aimed at improving tolerability and activity. Neoleukin utilizes advanced computational methods for its de novo protein therapeutics, addressing cancer and autoimmune diseases.
FAQ
What is the market cap of Neoleukin Therapeutics (NLTX)?
What does Neoleukin Therapeutics, Inc. do?
What is the recent reverse stock split about?
How does the reverse stock split affect stockholders?
Why did Neoleukin restructure its operations?
What are the notable technologies used by Neoleukin?
What is the impact of the proposed merger on Neoleukin's stock?
How can investors contact Neoleukin Therapeutics?
What is the significance of the de novo protein design technology?
Does the reverse stock split affect the company’s Nasdaq listing?
Where can I find more information about Neoleukin's recent developments?
